

Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD

NCT06714526

Status	RECRUITING
Phase	Not Applicable
Sponsor	Sunnybrook Health Sciences Centre
Enrollment	100 participants

Key Eligibility Criteria

Inclusion (4)

- Age ≥ 40 years old, male and female.
- TIA or ischemic stroke secondary to symptomatic atherosclerotic stenosis of 30- 99% involving the intracranial ICA or MCA or posterior circulation arteries as evidenced by CT or MR angiography.
- Index TIA or ischemic stroke event occurred within past 30 days.
- Clinical indication for DAPT for at least 3 months.

Exclusion (14)

- Any contraindication to DAPT.
- Any contraindication to use of clopidogrel (Plavix) or ticagrelor (Brilinta), such as pregnancy. A pregnancy test will be performed on all women of child-bearing age prior to enrollment in the study.
- Indication for chronic anticoagulation based on guideline recommendations or investigator's judgment (e.g., atrial fibrillation, mechanical heart valve, intracardiac clot, dilated cardiomyopathy, ejection fraction <30%, etc.).
- Intracranial arterial occlusion (i.e. 100% stenosis) responsible for the acute brain ischemia.
- Intracranial arterial stenosis secondary to causes other than atherosclerosis.
- ... and 9 more (see full listing online)

Locations (2 total)

University of Calgary, Calgary, Alberta, Canada
Dr. Mark I. Boulos - Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada